LOW/ZERO VOC GLYCOL ETHER-ESTERS AS COALESCENTS FOR AQUEOUS POLYMERIC DISPERSIONS

3178891 - EP16202342B1 - EPO

Application Mar 16, 2012 - Publication Oct 21, 2020

Linda A. ADAMSON Sarah E. ITTNER Michael C. BECKER Thomas R. TEPE Felipe A. DONATE Rebecca J. WACHOWICZ David Michael FASANO

SOLAR CELL MODULE

3570332 - EP19178798B1 - EPO

Application Jul 06, 2016 - Publication Oct 21, 2020

Chunghyun LIM

MAIN SPINDLE DEVICE FOR MACHINE TOOL

3725460 - EP17934908A1 - EPO

Application Dec 15, 2017 - Publication Oct 21, 2020

Seiji KAMIURA Motoki MURASE

A main spindle device (10) for a machine tool that checks the seating of a tool holder (30) using compressed air, wherein the main spindle device (10) for a machine tool comprises: a main spindle (12) that has a distal end face (18) in close contact with a flange end of the tool holder (30); an annular recess (25) that is formed on the distal end f...

INFORMATION PROCESSING SYSTEM AND METHOD

3264413 - EP15883334B1 - EPO

Application Nov 11, 2015 - Publication Oct 21, 2020

Shinichi KAWANO Yuhei TAKI

SWITCH LOCK DEVICE FOR RAILWAY SWITCHING ACTUATORS

3564090 - EP18305550B1 - EPO

Application May 02, 2018 - Publication Oct 21, 2020

Stefano BITTONI Andrea BORROMEI-COLOZZI

STRUCTURE MICROELECTRONIQUE A AMORTISSEMENT VISQUEUX CONTROLÉ PAR MAÎTRISE DE L'EFFET THERMO-PIEZORESISTIF

3558862 - EP17832289B1 - EPO

Application Dec 22, 2017 - Publication Oct 21, 2020

Guillaume JOURDAN Guillaume LEHEE

HETEROGENEOUS CHANNEL MATERIAL INTEGRATION INTO WAFER

3063788 - EP14766337B1 - EPO

Application Sep 03, 2014 - Publication Oct 21, 2020

Stanley Seungchul SONG Choh Fei YEAP Zhongze WANG Niladri Narayan MOJUMDER

COMBINATION THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER

3725810 - EP20163993A1 - EPO

Application May 21, 2013 - Publication Oct 21, 2020

Ugur SAHIN Özlem TÜRECI Rita MITNACHT-KRAUS Stefan Denis JACOBS Magdalena Jadwiga UTSCH Cornelia Adriana Maria HEINZ Christiane Regina STADLER

The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and met...